Disclosures

Prof. Wojciech Jurczak, M.D., Ph.D.

Advisory Boards :

Sandoz Novartis, Roche, Janssen, Acerta, Merck, Abbvie, Gilead,TG Therapeutics, Teva, Takeda, NovoNordisk, Servier

Research Funding:

Celgene, Abbvie, Gilead, TgTherapeutics, Janssen, Acerta,, Merck, Begene, Pharmacyclics, Pfizer, Roche, Sandoz – Novartis, Takeda, Teva, Servuier, Dova Pharmeceuticals, .

Polish Lymphoma Research Group

POLSKA UNIA ONKOLOGII

Poland&East European Branch of I.C.O.S. International CardiOncology Society

UNIWERSYTET JAGIELLOŃSKI COLLEGIUM MEDICUM

mcm małopolskie centrum medyczne

EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH

Polish Lymphoma Research Group

POLISH EXPERIENCE IN HL

Prof. Wojciech Jurczak MD,PhD

Polish Lymphoma Research Group

The predictive role of PET1 after ABVD in advanced HL

N = 204
PFS – 77 % at 3 yrs
OS – 92 % at 3 yrs

	Advanced stages patients
N[a]	204
Deauville score of iPET1	
1	2 (1%)
2	52 (25%)
3	79 (39%)
4	51 (25%)
5	20 (10%)
N[b]	184
iPET1(–)	
No	131 (71%)
Clinical outcome	
Progression/relapse	10/5 (12%)
Death	10
HL	2
Toxicity	4
Other	4
PFS	
At 3 years (95% CI)	0.84 (0.78–0.91)
NPV	84%
95% CI	79–87
iPET1(+)	
No	53 (29%)
Clinical outcome	
Progression/relapse	10/11 (40%)
Death	8
HL	7
Toxicity	1
Other	0
PFS	
At 3 years (95% CI)	0.57 (0.43–0.71)
PPV	42%
95% CI	32–52



Zaucha et al., AnnOncol 2017

Polish Lymphoma Research Group

Worse results in elderly patients with advanced HL

N = 264
EFS – 53 % at 3 yrs
OS – 81 % at 3 yrs

	EFS			OS		
Prognostic factor	HR	*p*	95%CI	HR	*p*	95%CI
Age ≥70 vs. < 70 years old	1.83	.0021	1.25–2.69	2.53	.002	1.4–4.55
Sex (male vs. female)	1.03	.88	0.73–1.44	1.16	.5	0.67–2
HL subtype (MC + LD vs. all others)	1.4	.065	0.98–2.01	0.59	.063	0.97–2.95
B-symptoms (Yes vs. No)	1.37	.18	0.87–2.16	1.64	.22	0.74–3.64
Presence of bulky disease	0.74	.21	0.46–1.19	0.33	.034	0.12–0.92
Extranodal disease (Yes vs. No)	1.78	.0089	1.15–2.73	1.73	.11	0.89–3.37
ECOG (≥ 2 vs. < 2)	1.84	.0033	1.23–2.77	1.61	.14	0.92–1.74
Any comorbidity (any vs. none)	1.47	.025	1.05–2.07	2.81	.00047	1.57–5.01
Cardiovascular disorder (any vs. none)	1.77	.0014	1.25–2.51	3.22	.000027	1.87–5.56
Albumin (<39g/L vs. ≥39g/L	1.09	.7	0.68–1.73	0.83	.63	0.38–1.79

HL: Hodgkin lymphoma; MC: mixed cellularity subtype of HL; LD: lymphocyte depletion subtype of HL; ECOG: Eastern Cooperative Oncology Group performance status; EFS: event free survival; OS: overall survival; HR: hazard ratio; 95%CI: confidence intervals.

EFS



Wróbel et al., Leuk.Lymphoma 2018

ECHELON-1 – benefit of BV despite age

N = 664 (in BV+AVD arm)
mPFS – 82 % at 3 yrs

Subgroup	A+AVD	ABVD	Hazard Ratio (95% CI)
	no. of events/total no. (%)		
Overall	117/664 (17.6)	146/670 (21.8)	
Age			
<60 yr	93/580 (16.0)	117/568 (20.6)	
≥60 yr	24/84 (28.6)	29/102 (28.4)	
<65 yr	99/604 (16.4)	128/608 (21.1)	
≥65 yr	18/60 (30.0)	18/62 (29.0)	
<45 yr	70/451 (15.5)	83/423 (19.6)	
≥45 yr	47/213 (22.1)	63/247 (25.5)	

mPFS



Connors, Jurczak et al., NEJM 2018

The predictive role of PET2 after esc.BEACOPP in advanced HL

N = 188
PFS – 80 % at 10 yrs
OS – 90 % at 10 yrs

	N	CR N (%)	PR N (%)	SD + PD N (%)
PET2 negative	141	129 (91.5%)	1 (0.7%)	11 (7.8%)
PET2 positive	47	32 (68.1%)	3 (6.4%)	12 (25.5%)
All patients	188	161 (85.7%)	4 (2.1%)	23 (12.2%)



Dlugosz Danecka, Jurczak et al.,
Pol.Arch.Int.Med. 2019

Polish Lymphoma Research Group

Polish Experience in Targeted therapy (R/R HL)

Brentuximab vedotin



Walewski et al., Br.J.Haemat, 2017

Nivolumab



Długosz Danecka et al., Acta Haematol Pol. 2019

Polish Lymphoma Research Group

Prof. Wojciech Jurczak, M.D., Ph.D.
Dpt of Hematology, Jagiellonian University
wojciech.jurczak@uj.edu.pl, (+48 602 338290)

Polish Lymphoma Research Group